Gabapentin Lawsuit: One Open Claim, No Dementia Class Action
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
Three different things travel under the name “gabapentin lawsuit.” The only one paying anyone is a price-fixing case: gabapentin 600 mg and 800 mg tablets are on the drug list of the $533 million generic drug settlements, and the claim deadline is November 9, 2026. The newer dementia lawsuits are individual cases — as of October 2026 there is no gabapentin class action for dementia, no settlement and no claim form. The old Neurontin marketing cases closed years ago.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Gabapentin Lawsuits Are About
1. Price-fixing (open claim). In the generic drug antitrust case, the lawsuit claims that generic manufacturers conspired to inflate prices, so consumers and health plans overpaid for a long list of “Named Generic Drugs.” Item 94 on that list is gabapentin tablets, 600 mg and 800 mg. The defendants deny any wrongdoing.
2. Dementia (no class action). Newer lawsuits allege that long-term gabapentin use contributes to dementia or mild cognitive impairment and that warnings were inadequate. They lean on a 2025 study in Regional Anesthesia & Pain Medicine of 26,416 adults with chronic low back pain: patients with six or more gabapentin prescriptions had a higher incidence of dementia (relative risk 1.29) and mild cognitive impairment (1.85). The study is observational and does not show that gabapentin causes dementia.
3. Neurontin marketing (closed). Neurontin is brand-name gabapentin. The FDA approved it in December 1993 solely for add-on seizure treatment; the Justice Department said it was then promoted for bipolar disorder, pain disorders, migraine and other unapproved uses.
Case Details
The open settlement belongs to In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:16-MD-02724, in the U.S. District Court for the Eastern District of Pennsylvania, before Judge Cynthia M. Rufe. Our news report covers the claim mechanics in detail: generic drug settlement claim form. The official site is GenericDrugsEndPayerSettlement.com.
The Neurontin marketing cases were consolidated in 2004 as In re Neurontin Marketing, Sales Practices and Product Liability Litigation, MDL-1629, in the District of Massachusetts; the third-party-payer class case is Harden Manufacturing Co. v. Pfizer, Inc., No. 1:04-cv-10981.
The dementia claims have no shared court: as of October 2026 they are being filed as individual cases, according to Drugwatch, a legal-information site.
Status as of October 2026: Claims Open Until November 9, 2026
Dementia lawsuits: no class action, no MDL. As of October 2026 there have been no jury trials and no announced settlements, per Drugwatch. There is no fund, no claim form and no deadline to file with anyone — personal statutes of limitations still apply.
Neurontin marketing: closed. Pfizer settled the third-party-payer claims for $325 million, with final approval in November 2014. Consumer suits were dismissed. Nothing is payable.
Don't miss the claim deadline
Claims are due by November 9, 2026. We'll email you 7 days and 1 day before the deadline.
Who Can File the Gabapentin Claim
You may be in the settlement classes if you paid for, or reimbursed, gabapentin 600 mg or 800 mg tablets (or another Named Generic Drug) for personal use, other than for resale, between May 1, 2009 and December 31, 2019, in any state except Indiana and Ohio, or in the District of Columbia, Puerto Rico or the U.S. Virgin Islands.
Check what you actually paid for. On the Appendix A list we reviewed, gabapentin appears only as 600 mg and 800 mg tablets — not capsules or other strengths. Consumers whose purchases were covered by Medicaid are excluded. A copay you paid out of pocket counts; a cost your insurer fully paid belongs to the insurer.
Proof is required. The claim form must come with supporting documents — pharmacy printouts or receipts showing the drug, strength and what you paid.
How Much the Gabapentin Settlement Pays
Payments are pro rata: your share depends on how much you spent on the Named Generic Drugs from May 1, 2009 through December 31, 2019, and on how many valid claims are filed. No per-person figure has been published, and gabapentin is one drug among many on the list, so a few years of copays on one generic may add up to a small check.
For the dementia lawsuits: no settlement, no fund, no claim form. Any dollar range you see is a law-firm estimate, not a court figure.
How cases like this one end
Our copy of the federal courts’ own case database covers 6,659 antitrust casesclosed in U.S. federal district courts between 2015 and 2025, 37.3% of them filed as class actions:
- 19.7% ended in a settlement recorded by the court. Another 14.4% were dismissed voluntarily, which often follows a private settlement — so the real settlement share sits between 19.7% and 34.1%.
- 11.6% were decided on a motion before any trial.
- 1 in 121 reached a trial (0.8%), after a median of 37 months.
- Median time from filing to the end of the case: 12.3 months.
- Almost none record a money award in this data (32 of 6,659), and the recorded figures are capped, so we do not publish an average.
These are base rates for this type of case (federal antitrust cases) — not a prediction about this lawsuit, and not legal advice. Source: Federal Judicial Center, Integrated Database (civil), analysed by Settlement Insight. Cases heard in state courts are not included.
Gabapentin Lawsuit Timeline
- 1
December 1993 — Neurontin Approved
The FDA approves Neurontin solely for add-on anti-seizure use in epilepsy patients.
- 2
May 13, 2004 — $430 Million Guilty Plea
Warner-Lambert agrees to plead guilty and pay more than $430 million over off-label promotion. Private suits are consolidated as MDL-1629 the same year.
- 3
November 2014 — Neurontin Payer Deal Approved
The court grants final approval of Pfizer's $325 million settlement with health plans. Consumer marketing suits are dismissed.
- 4
2025 — Dementia Study Published
A study of 26,416 chronic back-pain patients reports higher dementia incidence with six or more gabapentin prescriptions. Dementia lawsuits follow.
- 5
July 10, 2026 — Claim Notice Published
A court-authorized notice announces final approval of four settlements worth $533 million; consumers and health plans, including gabapentin tablet buyers, can now file claims.
- 6
November 9, 2026 — Claim Deadline
Last day to file online or postmark a paper claim. As of October 2026, the dementia cases remain individual suits with no settlement.
Three Things to Watch For
An open deadline on a common drug, plus lawsuit ads about dementia, is a combination that attracts imitators:
Claims firms that charge a cut
The court notice says class members do not need to sign up with a claims recovery firm or pay another law firm. The claim form is free on the official site or by calling 1-877-316-0171.
“Gabapentin dementia settlement” payout offers
There is no dementia settlement and no fund. A message promising a dementia payment, or asking for your Social Security number and medical records to “reserve” one, is not from a court.
Look-alike claim sites
Type GenericDrugsEndPayerSettlement.com yourself instead of following links in texts or ads. A real administrator never asks for a fee or gift cards to process your claim.
Gabapentin Lawsuit — Questions People Actually Ask
Is there a gabapentin class action lawsuit I can file a claim in?
Yes, one: the generic drug price-fixing settlements. If you paid for gabapentin 600 mg or 800 mg tablets between May 1, 2009 and December 31, 2019 (outside Indiana and Ohio), you can file a claim by November 9, 2026. It pays for overcharges, not for side effects.
Is there a class action lawsuit gabapentin dementia patients can join?
No. As of October 2026 there is no gabapentin class action for dementia and no MDL; claims are being brought as individual lawsuits. There is nothing to join or register for.
Can I file a lawsuit for gabapentin and dementia?
Some firms are screening cases; one set of criteria cited by Drugwatch requires at least six prescriptions between 2000 and 2024 and a diagnosis before age 65. That is a firm's intake rule, not a court standard, and no court has found that gabapentin causes dementia.
Who is the lawsuit against gabapentin makers aimed at?
Depends on the case. The price-fixing settlements are with Sandoz, Sun/Taro, Heritage and Apotex, while claims continue against other generic makers. The Neurontin marketing cases were against Pfizer and Warner-Lambert. According to Drugwatch, the dementia suits claim that Pfizer failed to properly warn doctors and patients of the dementia risk.
How much will I get from the gabapentin settlement?
Unknown until claims close. Payments are pro rata, based on what you spent on Named Generic Drugs and on the number of valid claims. Consumers draw from the $275 million Sandoz and $200 million Sun/Taro funds, after fees and costs.
What proof do I need?
Supporting documents showing you paid for a Named Generic Drug in the class period. Ask your pharmacy for a prescription history printout listing drug, strength, dates and your out-of-pocket cost.
Did the old Neurontin settlement pay consumers?
No. Pfizer's $325 million settlement, approved in November 2014, paid health plans and other third-party payers. Consumer Neurontin marketing suits were dismissed with prejudice. Nothing is left to claim.
I got a postcard about generic drugs. Is it real?
The court-authorized notices point to GenericDrugsEndPayerSettlement.com and 1-877-316-0171. If a letter uses a different site, asks for a fee or pushes you to a law firm, verify through the official site before giving any information.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.